Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by lscfaon Nov 15, 2021 9:43am
75 Views
Post# 34126637

RE:Negative gross margin

RE:Negative gross margin

Small operators more profitable...


Ayurcann
 

 

Qtr ending

Revenue

Gross profit

Margin

Op. Income

Jun21

2,659,087

2,313,898

87.0%

1,237,521

Mar 21

2,626,516

1,842,161

70.1%

1,008,754

Dec 20

1,560,073

302,132

19.4%

(38,231)

Sept 20

787,980

168,526

21.4%

(48,735)

Jun 20

602,376

476,426

79.1%

305,479

Mar 20

9,453

(105,026)

(1111.0%)

(321,601)

Dec 19

0

0

0

(42,099)

 

 

adastra

 

Revenue

Gross profit

Margin

 

 

 

 

 

 

 

 

Q2 21

1,241,763

545,641

43.9%

Q1 21

589,138

186,922

31.7%

Q4 20

1,245,097

620,044

49.8%

Q3 20

825,903

(49,582)

(6.0%)

Q2 20

428,355

215,119

50.2%

 





lscfa wrote: How about some transparency. Recall when LABS, VLNS and others where bragging about how much processing capacity they were building out. Now there is not a peep from any of them about how much capacity they have. This over-building is showing up as a big depreciation expense in costs of revenue. They need to scale up the business to turn a gross profit. 

 

<< Previous
Bullboard Posts
Next >>